Imaging Bio Share Chat (IBAI)

Red are you buying up shares cheap again?

If not Red, then somebody is and MM’s helping with keep dropping the price

Thanks

Thanks malletp for all your insight it is appreciated

Have a good rest of the weekend

Tyke

Because that is market sensitivity information,.its unlikely to be disclosed. My personal is that it won't now happen until phase 0. - but I could be wrong. . The good news is that it could take as little as a month to find out if GaM is in the tumour. Although the trial is for 8, they can get a high probability result with 4. That's just one operation a week.

According to HL you can vote via their website (not app please see below) but IBAI AGM doesn’t appear yet, I assume too soon.

Worryingly it also displayed how much I paid for my first IQAI shares, 9.4p in April 2021. That is quite a decimation of the price. How good it would be to get back to them prices.

“We don't automatically send out notification of shareholder meetings or voting forms to clients who hold shares in an HL Account.

However, this doesn't stop you from partaking or voting in any future AGMs on any of the shares that you hold. If you'd like to attend an AGM or vote on a company’s shares that you hold, you can do so once logged into your account through our website by clicking on the View shareholder meetings link underneath your secure messages.

From here, you will be able to see all upcoming shareholder meetings for companies in which you own shares and submit a vote on the proposals or request to attend an upcoming meeting.”

Malletp maybe you could ask when the expect the phase 1 results to be published please. A few of us seem to be persona non grata when speaking to the company after what happened in January and don’t always get replies. It has been 3 months since we know they were submitted to a journal. That seems a very long time to get no information.

Thanks in advance

T

Thanks MalletP

Cautious - I couldn't agree more. Let's just leave it where it is (vote no). If the new strategy, stated in January is correct, they will start making money and the share price will naturally rise. It gives management an incentive to perform.. Otherwise, nothing will change.

"The directors believe it is no longer in shareholders' interests to embark on a Phase 2 clinical trial of gallium maltolate as previously intended. The financial and operational resources would be better employed to concentrate upon nearer-term commercial objectives of our imaging solutions.

Amy thanks for all your efforts Tyke. You are IB investor relations!

Tyke

that is really interesting. that is great. well done, thank you.

I think this is the key takeaway

“We remain open to partnership, licensing, or other structured arrangements that reflect the asset's underlying value, but our priority is organic growth in the core business. The same principle applies across the wider technology portfolio: we will advance and monetise these assets on terms that support long-term shareholder value, not near-term transactions at suboptimal valuations.”

So nothing is going cheap but we will need to wait for a return on our investments. As malletp says wait for the new clinical trial plus our data and then see what it’s worth then.

Thanks

I wonder if one of the parties interested in the Phase 1 data is Trueride....?

Tyke, great work!!!

-- BB --

Thanks Max

Not sure if we achieved anything but the board do now know we have over the 5% and no know how to contact the company secretary.

The new Modus Operandi would explain the lack of answers from Mike at times.

Anyway have a good weekend

Cheers

T

Have a good weekend everybody.

I can’t see us hearing anything before the AGM at this rate, unless there is something we don’t know about yet.

Thanks

T

Message from MS no update on phase 1 being published as of yet. He will share more when firm information.

Thanks

Tyke,

I emailed you this morning ...

-- BB --

You can also now vote via the HL website, it has updated.

Thanks

Any investors out there with AJ Bell ...you can vote through the app.

I just have ..

-- BB --

Further update from Joe at Apex

“I have confirmation that we will receive responses to your questions by e-mail so that I can send you a copy of the responses.”

Let’s see what answers we get

Thanks

A reply from Apex

Yes, your questions are fine and will be presented to the AGM

So just a reminder of the questions we have asked:

AGM questions

• What exactly is the new modus operandi and how will it increase shareholder value back, and beyond, to where it was prior to the sale of significant shares to Braveheart (now Truetide)?

•What are the revenues for the first 3 months of 2026 compared to 2025 and what are the projected revenues for the year?

•Have we had any discussions with other entities about the sale or licensing of our phase 1 data, and if so what valuation was discussed? Similarly any discussions on the sale of any of IB’s technology?

•Where have savings been made and what are the amounts saved?

•Can the sales of software be broken down by product eg IB Neuro and what are the projected revenues per product?

•Can the revenue be broken down per customer eg MCW, GEHC, Blackford etc and other users?

•How long do we expect the collaboration with Vivan Therapeutics to continue for and have we had any feedback on how successful it has been and the possibility of it leading to generating revenues in the future?

I hope these are all ok for everyone involved. It will be interesting to see what answers we get. I am just awaiting confirmation the replies will be in the written AGM results RNS, unless somebody fancies a day trip to Jersey to hear them firsthand. It would be interesting to see if it is all done by teams or zoom etc or in person.

Thanks

T

Linandy

This is one of the question we are hoping will be asked at the AGM

“Can the sales of software be broken down by product eg IB Neuro and what are the projected revenues per product?”

Let’s see if we find out what they expect to earn from IB Neuro?

Still awaiting a reply from apex, I will let everyone know when I hear back

Thanks

Hi Tyke hope your well, haven’t we been here before being told they will endeavour to reverse decline and interact with investors more!!!!

If it wasn’t for the fact this is now virtually worthless as a share I’d be long gone,

Thanks Max

Maybe the company could explain how with all this excellent work by MCW that the share price of IBAI has been decimated? What is their plan to rectify this etc?

Thanks

Https://files.imagingbiometrics.com/share/tumJWXoVDkYgsTKdotu0

Dr Marty Makary Has resigned from the FDA. Hopefully that will not have an effect on the vouchers as that could be a big selling point for the phase 1 data.

Thanks

I don't know whether any of you follow IBAI on LinkedIn – I do.

The output is frequent, interesting, informative, expressive and sometimes quite exciting.

But any potential investor or pharma exec would only have to dig down – even visit this site – to see that behind all the amazing science and possibilities is a company run by "amateurs".

'Trust' is the biggest word in any business, and the trust levels here are at zero.

It is such a shame.

-- BB --

Agreed, BB. To actually go through the calculation and state that reduced capital in the AGM notice and not realise how far out it was from their intentions is a ridiculous oversight.

And as you say not for the first time. As a further example, in the Annual Report just published they have finally fixed note 22 (prev. 21) to change Brett’s designation from Non-Executive Chairman to Non-Executive Director (in line with Tyke’s phone call comment earlier this year that they don’t have a Chairman) but they couldn’t be bothered to proof check the rest of the report for the other places it was wrongly stated. A simple electronic word check on ‘Chairman’ would have flagged them up for correction as well. Is that now 4 years running they have submitted an incorrect and misleading report to the Jersey Financial Services Commission?

Including:

“On an annual basis, the Chairman considers the performance of the Board and discusses with the Company Secretary the re-election process. Given the performance of the Company, the Chairman has confirmed that the Directors being submitted for election […] continue to be highly effective, qualified and committed to their respective roles.”

“highly effective” – apart from the financial reporting function it seems!

These errors should not be happening - repeatedly - in a stock market listed company. Unfortunately that’s one of the risks of small companies with few directors who’s functions repeatedly overlap and reduce the possibility of proper oversight and governance, but they should not be relying on anonymous posters on internet forums to proof read their legally required documents AFTER they have been published!

-\ end rant.

Ahhh yes the Bank of Trevor!

I am quite sure this is not the first time that an IQAI/IBAI RNS has had to be amended ... and I am quite sure it will not be the last.

Spelling mistakes I can cope with, BUT getting figures wrong is simply unforgivable ... this is a business ...

Oh wait, maybe it's just a bank ...

-- BB --

And they couldn’t even get that right. Surely you check the wording of an Rns before submitting. Then again on 100k a year probably not

Max your not saying updates have been withheld and the price has been orchestrated to this range?

I would like to know we’re the 29.35 held by trutide is sitting now?

Maybe some fireworks today?

Max why haven’t the results being published in any journal yet. I honestly believe that is why the results and AGM are being delayed. But MCW/JC/CC are the leads so they control the narrative rather than IB. I still wonder if malletp has some inside information , no disrespect if you haven’t but your observations are very pertinent and thank you for them.

Thanks

Contrary.

Mr Brown has numerous times stated phase 2 plans in development either with partner or on our own pump pump pump !! Deviously changing plans ! It’s evident things going on behind our backs post phase 1 finish so I’m not ruling a phase 2 out . Disturbing is his much the greedy coach-a-roach wants

Mr Brown clearly stated that they had used scarce resources on GaM development, starving the core software business of the limited resources they had. The pivot back to software was the reason not to proceed with phase 2. What i think will happen is that the rights to GaM will be sold in due course. The phase 0, shortly underway, is almost certainly a response to the feedback MCW got on the unpublished phase 1 results. We know there was a signal - but they were probably told "go back and prove the drug is in the tumor - then come back". My hunch is that IBs GaM IP and the pediatric designation rights will then be packaged with the phase 0 data and sold. How much is that worth to a US pharma? Probably more than the market cap right now.

Whatever the precise mechanism is, we know the main reason is almost certainly to allow the issue of further shares - and the price is unlikley to be even the 0.75p. It's time this stopped. Personally, I will not be supporting that resolution. Most retail brokers allow you to vote on the resolutions with the click of a button - check the Corporate Actions section in your broker account. You will almost certainly get an invitation to vote.

Crazy when you think this used to trade over 15p

It's 0.05 pence

• one-twentieth of a penny

• five hundredths of a penny

Mistake or is this really happening

-- BB --

It's NOT 1/2 a pence ...

** fundraise may be on the way ** (see below)

This is essentially an accounting and share-structure change, not an immediate change in the company’s value.

Imaging Biometrics Limited is proposing a “share sub-division” (also called a stock split).

Current structure:

Each ordinary share has a nominal/par value of £0.01 (1 penny).

Proposed structure:

Each ordinary share would instead have a nominal/par value of £0.0005.

The important line is:

“without altering the total of 246,709,789 shares outstanding.”

That means:

The number of shares you own does not change.

The total number of shares in issue does not change.

Your percentage ownership does not change.

The company’s market value does not automatically change.

So what is actually changing?

Only the “nominal value” (sometimes called face value or par value) attached to each share in the legal company records.

Example:

Before:

1 share = nominal value £0.01

After:

1 share = nominal value £0.0005

This is mostly a technical/legal restructuring.

Why companies do this:

Common reasons include:

Creating more flexibility for future fundraising.

Making the capital structure more suitable for growth or acquisitions.

Reducing the nominal value so new shares can be issued at lower prices without legal complications.

Preparing for future corporate actions.

What it does NOT necessarily mean:

It does not automatically mean the company is worth more.

It is not automatically dilution.

It is not automatically positive or negative.

The wording is slightly unusual because many share subdivisions increase the number of shares (e.g. 1 share becomes 10 shares). Here, they explicitly state the total shares outstanding will remain the same, suggesting this is primarily a reduction in nominal/par value rather than a traditional investor-facing stock split.

The AGM on 3 June 2026 is where shareholders vote on approving it.

RNS OUT

They must have read my message. The annual reports is now on the website but no AGM notification yet.

Thanks

Don’t get too excited. Its been like this for yrs

You start thinking something good may occur, . Then Brown comes along and chops your legs off

Truetide up by 22%. Is something bubbling over there related to over here?

Linandy

If that is the case hopefully TB gets fed up and sells it for as much money as possible asap.

Thanks

Max

We are still waiting for the phase 1 result RNS where it says how IB003 increases overall survival time. Then it will mention how we aren’t sponsoring a phase 2 trial.

That will cause a drop unless we have a buyer/licensee lined up.

Thanks

The demolition of this share has led us to having a RNS and no drop ! Amazing keep up the good work TB new beginings .

Common reasons:

Insider filing technicalities

Executives/directors sometimes receive:

stock grants,

vesting adjustments,

dividend reinvestments,

compliance corrections,

account transfers.

These can generate Form 4 filings showing 1-share transactions. They may simply be bookkeeping entries rather than meaningful buys.

Testing or account verification

Brokerages, transfer agents, or automated trading systems occasionally use 1-share transactions to:

test settlement systems,

verify accounts,

activate trading permissions,

reconcile holdings.

Maintaining insider status

In some cases, an executive may buy a token amount to:

establish ownership,

maintain a reporting relationship,

demonstrate nominal alignment with shareholders.

A 1-share purchase has almost no financial significance unless the share price is extremely high.

Automated dividend reinvestment rounding

Dividend reinvestment plans (DRIPs) can occasionally round fractional holdings into whole shares, producing tiny transactions.

Optics / signalling

Rarely, insiders buy very small amounts as a public confidence signal. However, markets usually ignore tiny purchases because conviction is judged by:

total value purchased,

number of insiders buying,

whether purchases are open-market buys,

whether purchases are unusually large relative to salary/net worth.

Ten separate 1-share buys are generally less meaningful than:

one insider buying £50k+ worth of shares, or

multiple executives buying substantial amounts within 30 days.

Thanks Max

Never use AI

Maybe they know the phase 1 results and think we are going to be the new Apple or nvidia.

Still no notice of the AGM either

Thanks

AI will give you a few ideas Tyke

I’ve no idea what it’s telling me 🤷🏼‍♂️

Cautious (and Max)

How about we change the question to

How long do we expect the collaboration with Vivan Therapeutics to continue for and have we had any feedback on how successful it has been and the possibility of it leading to generating revenues in the future?

Thanks

Thanks Max

It may still be worth asking the question to see if they think the partnership may lead to future revenue?

Thanka

Small amount of info from Vivan , trials on going but halted for a while due to funding , this pilot scheme is of no cost to IB. Vivian since acquired more funding and studies back in progress .

Thanks try that takes us over 18m shares

Cautious what about:

are we still collaborating with Vivan Therapeutics and if so have we had any feedback that may increase the value of our GaM phase 1 data in the future?

Thanks Xviolet, it is appreciated

Thanks

Tyke. Interested in knowing any outcome regarding the strategic partnership with Vivan Therapeutics

Thanks Xviolet

what about:

can the revenue be broken down per customer eg MCW and other users?

Thanks

T

Size of holding....there's a few accounts here and there

but one of them has 400,000 in it.

so add that to the pot.

Tyke

I have one question.

Can IBAI please breakdown the sources of revenue according to percentages. So if 50% of the revenue is coming from MCW please let us know. Please let us know what the figure is. Similarly with regards to Eastern Alabama Medical Centre - what percentage of revenue comes from that license. I would like to see a breakdown of revenue according to customer.

I have always assumed 90%+ was from MCW which is why I lose no sleep over the trial sponsorship details.

So I would like to see a breakdown that tells us what percentage of revenue comes from what source - MCW, Eastern Alabama, Blackford etc.

Sorry forgot to say we are now over 6% shareholding. How may people want to send a message and use their voice to ask a question or two?

Thanks

Kane

I have been saying for a while there could be issues between IB and MCW but I don’t think we would ever get an answer about that. Hopefully what we could see is both the imaging side and/or GaM data being sold because of internal tensions. What we don’t want is a Stonechecker situation

Thanks

Combining questions from people we have the following so far:

• what exactly is the new modus operandi and how will it increase shareholder value?

•what are the revenues for the first 3 months of 2026 compared to 2025 and what are the projected revenues for the year?

•have we had any discussions with other entities about the sale or licensing of our phase 1 data?

•Where have savings been made and what are the amounts saved?

•can the sales of software be broken down by product eg IB Neuro and what are the projected revenues per product for this year?

Are there any other (sensible) questions people would like to add?

With Red, Max and I (CL just awaiting your confirmation of it being 0.9m) we have just short of 10m shares or nearly 4%. How many more shares do we own as a group?

Phil has already mentioned PYC and what has happened there. I am not suggesting that but we do need far more information being shared with shareholders in my view. The more we show we own of the company the louder are voice should be heard.

Thanks

T

Can someone post a link to the AGM resolutions once it is available for viewing.

It is highly important that the current board back the plan to profitability in financial year 2026. Whilst I appreciate that the Truetide/TB concert party holding is close to 30%, which makes it difficult to add shares on the open market, I want to see our board highly incentivised with their AGM options. Under no circumstances should director fees be cut, if they are then to receive at the money options. After all, it was the TB family sale of shares that was largely responsible for the big fall in the share price.

The days of cancelling historical options and replacing them with at the money options, must also be truly over. If not, I can see a PYC type overhaul taking place.

I wonder whether MS and/or KS are considering an open market purchase, given no placing is required?

Why was it released so late in the day? So hopefully it doesn’t make the sp drop too much tomorrow maybe.

On first read it doesn’t tell us anything we didn’t already know. What would have been nice is an update on how revenue has being going this year so far. If they expect us to break even this year they need a significant increase in sales so has that happened.

I think we need to think about asking pertinent questions at the AGM. Sensible suggestions only please. eg

• what exactly is the new modus operandi and how will it increase shareholder value?

•what are the revenues for the first 4 months of 2026 compared to 2025?

•have we had any discussions with other entities about the sale or licensing of our phase 1 data?

BB could you possibly publish that email address again please and let’s see what question we should ask and how many shares we now hold between us?

This is just going to keep drifting along unless we get some positive news.

We need to be united again

No ambiguity, just (clear) answers please.

Thanks

Yes it’s their actions that have caused this annomoly in share price.

We bought this all the way up to 6p for the directors just to let their families sell and now we’re here if OUR directors are so confident then buy some shares and prove it!

Until then it’s the same old over promising and under delivering mixed up with some fancy words.

From memory this is the 3rd end of year report that promises a step change in revenue.

Yes it’s their actions that have caused this annomoly in share price.

We bought this all the way up to 6p for the directors just to let their families sell and now we’re here if OUR directors are so confident then buy some shares and prove it!

Until then it’s the same old over promising and under delivering mixed up with some fancy words.

From memory this is the 3rd end of year report that promises a step change in revenue.

Deja vu

Directors need to buy shares money where the mouth is !!

"Your directors are confident that 2026 will be a year of revenue acceleration and bottom-line delivery and believe that the current share price does not fully reflect the progress made and the near-term growth opportunities ahead."

And it didn’t disappoint. What an effing joke

Same old rubbish.

-- BB --

Thanks Corryvreckan1

Phil

Just reading the PYC information. Very interesting, thanks

T

I think it's seven months for Jersey Companies under their regulations, and Jersey is classed by the FCA as a "third country" i.e. overseas for their listing rules, so they give equivalency to them so they get an exemption from the UK reporting requirements as long as they fully comply with Jersey regs.

In practice many Jersey companies will comply with the regs in the country in which their shares are listed as it's generally considered to be good practice to do so and meet shareholder expectations there. I'm expecting them tomorrow and they have always followed the UK deadline in the past. Now is not the time to be changing...

That's my understanding, not advice.

Thanks Tyke.

I presumed, as Imaging Biometrics (IBAI) has a Main market listing, annual results are required to be delivered on or before 30 April 2026, otherwise the shares will be suspended. This would remain the case, until they are released, for a maximum of six months. Then the shares would be delisted.

Does this apply for companies registered in Jersey?

Phil

Thanks Tyke

Good luck

Kane

You mentioned previously selling at 19p I believe. I would guess most people here could only hope for that. Unfortunately we aren’t all in that position and I think for example M-Oz said his average was double digits. People need to be able to recoup their losses. So the last thing we need is the company to be liquidated.

Thanks

It’s getting to the point where I would welcome very much so the insolvency rns that cant be too far away as it means we aren’t being lied to anymore.

It would also mean a certain someone can’t draw £100k per year for his efforts here. If he’s taking 100k again this year then that’s crazy we would need to group together to sort out this mess. Unfortunately the best way forward here considering how crap and uninvestable this company has been made to be. They state they have contracts with GE but show no revenue??? If you go through every past rns you could potentially see that almost everything promised by the bod has been a lie or never achieved.

Sadly the best option here is the company put out of business. It’s pretty much been out of business considering how useless the bod have been and completely silent. And the bod here should never be allowed to run another listed company

Kane from last year’s annual report

“The Company currently has no debt, a large bank of IP, and the potential of revenue and further value realisation from the Clinical trial and EAP initiatives and developed products. ”

From the half year report

“ The Chief Executive Officer has provided a letter of financial support to the Group to make sufficient funds available, if required, to ensure the Group can meet its obligations over the going concern period.”

So the last thing we want to think about is liquidation.

Thanks

Unfortunately we have been shafted by the scientists at mcw and also the bod here that’s supposed to protect ALL shareholders interests. How none of them havent resigned yet is a joke. They have achieved nothing literally nothing for over 5 years and wasted millions of investors money and now they hide under a rock. I really think a group of us should go to the agm this year just to look them in the eye and tell them how we feel and the changes we want to see!! I know they don’t care but just to make them feel uncomfortable for 10 minutes would be a nice thing to see.

I just can’t believe the silence here and how they’re getting away with the complete radio silence.

What’s going on with kirstal ??? Actually what’s going on with anything?? Does Kathleen still care or want her shares to improve in value or is she getting a better deal from mcw so she doesn’t really care??

Something has to change here big time or they should put shareholders out of their misery and pull the plug it’s beyond a joke now

It’s getting to the point where I would welcome very much so the insolvency rns that cants be too far away as it means we aren’t being lied to anymore.

Is semantic part of the company? If so can he be classed as an insider? If so, all his posting of AI quotes stating the values of phase 2 compared to phased 1 can that with hindsight be classed as misleading investors?

All the RNSs over the last 2 years saying going to be meeting the FDA etc which have never actually occurred. Is that classed as misleading investors?

TB and family selling his shares at 1.1p compared against the current sp of 0.57p which has never been explained. The statements saying we all shareholders, is that factually wrong if TB doesn’t hold any shares in IBAI directly?

MCW are doing very well out of all this but what about IB/IBAI shareholders?

No ambiguity, just answers seems to have been written the wrong way round. No answers, just ambiguity!

It will be interesting to see if Apex actually reply.

Let’s see what next week brings and if we get any answers. Maybe TB will quote the downfall of Sinclair rather than comparing us to Apple?

Fingers crossed we get a pleasant surprise.

Thanks

Thanks Xviolet

I think you have hit the nail on the head. We invested in the company because we trusted what we had been told about GaM. That was until we got the January RNS, then the trust evaporated overnight.

Thanks, good luck

I think it is improbable that the Medical College of Wisconsin would be involved in a predatory move to seize value from IBAI's IP. I have never attended or scrutinized this Medical College but I still think that is a very unlikely scenario.

There is a point where if you invest in a company you have to trust the company. And I think you also need to know the field - you would need to know pharma, company law etc. I don't know that stuff so I have tailored my investment and my opinions according to my level of knowledge.

Thanks Xviolet

It is nice to know Mike replies to some people.

A couple of points you raised:

MCW own the rights to the Gabriel trial data even though they seem to be based on our trial data experience by the MCW staff. That seems like we have wasted our time if they can (what’s stopping them) then apply for subsequent RPDD vouchers. That’s $200m possibly wasted.

Also the “referencing” bit you imply other studies can’t reference “that does not mean that additonal academic studies can reference the existing Phase 1.” but then say maybe MCW is just referencing. Did you mean they can reference our data?

Unfortunately we seem to have wasted years on GAM but we are going to let others gain the financial rewards. A lot of people invested based on the GAM trial so the company should try to gain some financial rewards somehow.

Let’s see what the annual report says. Thanks for letting us know the details.

Thanks

Hi Tyke

Yes I received a very polite and interesting email from Michael. Which I am still studying. However Michael confirmed - as you probably know - that Imaging Biometrics has commercial rights to the Phase 1 trail results (of GaM in adult GBM'. eived.

He also confirmed that the data from the trial sponsored by the Medical College of Wisconsin will be owned by MCW.

Michael outlined the journey from Phase 1 clincial data to commercial returns. And I think most of us have a reasonable picture of that journey. And as we know that is not happening at the moment. IBAI is not going to fund its own Phase 2 trial.

Perhaps an interesting point is that while IBAI is not going to pursue its own Phase 2 - at present - that does not mean that additonal academic studies can reference the existing Phase 1. So perhaps the MCW study is 'referencing' the IBAI study rather than being a move to steal or take value from IBAI.

My own take...that value may be very challenging to realize.

we're gonna be here for a long time. which is good as I still have more research to do on this company.

Xviolet

If we want to retain staff then we need to think about hitting these sp’s (and well above to make them worthwhile)

“The following Options were granted to key non-Board IB staff and service providers:

Options Granted

Exercise Price

Vesting Schedule from the date of grant (February 2025)

1,000,000

£0.0145

50% after 1 year and the balance after 2 years

550,000

£0.0145

50% after 1 year; 25 % vests after 2 years; the balance vests after 3 years

Up to 6,000,000

£0.04

1 000 000 vests after 1 year; each remaining tranche of 1 000 000 vests upon a qualifying sale of IB Nimble, but not before the first anniversary of the grant

All Options held by IB staff are subject to continued employment at the time of vesting.”

The 6000000 shares person would only make £120k if the sp hits 6p. Have they got a buyer lined up for Nimble? The 1 year anniversary is up already.

I think if we got above 4p we might all be more positive.

Maybe we will find out more next week with the annual results, assuming they aren’t delayed.

Thanks, have a good rest of the weekend

Xviolet did the company reply to your questions?

Thanks

Set a bit higher than the current sp?

so....in time we should be there. it does look like there's quite a lot of £ to be moved on those CLNs back to TrueTide. so presumably something must happen here - something to create value and create interest - to make that so?